Lung Cancer
Volume 70, Issue 2 , Pages 211-217 , November 2010

Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy

  • Sachin Kumar

      Affiliations

    • Department of Medicine, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi 110029, India
    • ,
  • Randeep Guleria

      Affiliations

    • Department of Medicine, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi 110029, India
    • Corresponding Author InformationCorresponding author at: 4083 A, Teaching Block-4th Floor, Department of Medicine, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi 110029, India. Tel.: +91 11 26593676; fax: +91 11 26588641.
    • ,
  • Vikas Singh

      Affiliations

    • Department of Medicine, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi 110029, India
    • ,
  • Alok C. Bharti

      Affiliations

    • Division of Molecular Oncology, Institute of Cytology and Preventive Oncology, I-7, Sector-39, Noida, Uttar Pardesh 201301, India
    • ,
  • Anant Mohan

      Affiliations

    • Department of Medicine, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi 110029, India
    • ,
  • Bhudev C. Das

      Affiliations

    • Dr. B. R. Ambedkar Centre for Biomedical Research, University of Delhi (North Campus), Delhi 110007, India

Received 14 October 2009 ,Revised 28 January 2010 ,Accepted 30 January 2010.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Can J Clin. 2005;55:74–108
  2. Brambilla C, Fievet F, Jeanmart M, de Fraipont F, Lantuejoul S, Frappat V, et al. Early detection of lung cancer: role of biomarkers. Eur Respir J. 2003;21(Suppl. 39):36s–44s
  3. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 1999;354:99–105
  4. Pastorino U, Bellomi M, Landoni C, De Fiori E, Arnaldi P, Picchio M, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet. 2003;362:593–597
  5. Lacroix J, Becker HD, Woerner SM, Rittgen W, Drings P, von Knebel Doeberitz M. Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by preproGRP-specific RT-PCR. Int J Cancer. 2001;92:1–8
  6. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer—a survey. Biochim Biophys Acta. 2007;1775:181–232
  7. Pathak AK, Bhutani M, Kumar S, Mohan A, Guleria R. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem. 2006;52:1833–1842
  8. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136:260–271
  9. Gajalakshmi V, Hung RJ, Mathew A, Varghese C, Brennan P, Boffetta P. Tobacco smoking and chewing, alcohol drinking and lung cancer risk among men in southern India. Int J Cancer. 2003;107:441–447
  10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–216
  11. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646–650
  12. Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 2001;61:4675–4678
  13. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol. 2003;21:3902–3908
  14. Beau-Faller M, Gaub MP, Schneider A, Ducrocq X, Massard G, Gasser B, et al. Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int J Cancer. 2003;105:361–370
  15. Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chassé E, et al. Circulating deoxyribonucleic acid as a prognostic marker in non-small cell lung cancer patients undergoing chemotherapy. J Clin Oncol. 2004;22:4157–4164
  16. Xie GS, Hou AR, Li LY, Gao YN, Cheng SJ. Quantification of plasma DNA as a screening tool for lung cancer. Chin Med J. 2004;117:1485–1488
  17. Herrera LJ, Raja S, Gooding WE, El-Hefnawy T, Kelly L, Luketich JD, et al. Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin Chem. 2005;51:113–118
  18. Paci M, Maramotti S, Bellesia E, Formisano D, Albertazzi L, Ricchetti T, et al. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer. 2009;64:92–97
  19. Yoon KA, Park S, Lee SH, Kim JH, Lee JS. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn. 2009;11:182–185
  20. van der Drift MA, Hol BE, Klaassen CH, Prinsen CF, van Aarssen YA, Donders R, et al. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer. 2009;(July):
  21. Szpechcinski A, Struniawska R, Zaleska J, Chabowski M, Orlowski T, Roszkowski K, et al. Evaluation of fluorescence-based methods for total vs. amplifiable DNA quantification in plasma of lung cancer patients. J Physiol Pharmacol. 2008;59(Suppl. 6):675–681
  22. Fournie GJ, Courtin JP, Laval F. Plasma DNA as a marker of cancerous cell death: investigation in patients suffering from lung cancer and in nude mice bearing human tumour. Cancer Lett. 1995;2:221–227
  23. Lee TH, Montalvo L, Chrebtow V, Busch MP. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion. 2001;41:276–282
  24. Lui YY, Chik KW, Chiu RW, Ho CY, Lam CW, Lo YM. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem. 2002;48:421–427
  25. Sozzi G, Roz L, Conte D, Mariani L, Andriani F, Lo Vullo S, et al. Plasma DNA quantification in lung cancer computed tomography screening: five year results of a prospective study. Am J Respir Crit Care Med. 2009;179:69–74
  26. Zitt M, Muller HM, Rochel M, Schwendinger V, Zitt M, Goebel G, et al. Circulating cell-free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring. Dis Markers. 2008;25:159–165
  27. Holdenrieder S, Stieber P, VON Pawel J, Raith H, Nagel D, Feldmann K, et al. Early and specific prediction of the therapeutic efficacy in lung cancer by nucleosomal DNA and cytokeratin 19 fragments. Ann N Y Acad Sci. 2006;1075:244–257
  28. Holdenrieder S, von Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, et al. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer. 2009;63:128–135
  29. Gazdar AF. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med. 2009;361:1018–1020
  30. de Marinis F, Grossi F. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist. 2008;13(S1):14–20

PII: S0169-5002(10)00064-4

doi: 10.1016/j.lungcan.2010.01.021

Lung Cancer
Volume 70, Issue 2 , Pages 211-217 , November 2010

Article Tools

* Image Usage & Resolution